Comparative Pharmacology
Head-to-head clinical analysis: DICUMAROL versus SAVAYSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICUMAROL versus SAVAYSA.
DICUMAROL vs SAVAYSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
Direct inhibitor of factor Xa, thereby decreasing thrombin generation and fibrin clot formation.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
5 mg orally twice daily for nonvalvular atrial fibrillation; 5 mg orally twice daily for venous thromboembolism treatment after initial parenteral anticoagulation for 5-10 days.
None Documented
None Documented
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
Terminal elimination half-life is 10-14 hours; in healthy subjects, mean half-life is approximately 10 hours. Clinically, this supports once-daily dosing. Half-life is prolonged in renal impairment (e.g., up to 17 hours in severe renal impairment).
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Eliminated primarily via renal excretion of unchanged drug (approximately 82% of an oral dose is excreted in urine as edoxaban). Fecal/biliary excretion accounts for about 8%. Minor metabolism (<10%) via hydrolysis (mediated by carboxylesterase 1) and conjugation, with metabolites excreted renally or in feces.
Category C
Category C
Anticoagulant
Anticoagulant, Direct Factor Xa Inhibitor